Core Insights - Precision BioSciences has announced the issuance of a U.S. patent for its lead in vivo gene editing program PBGENE-HBV, which is aimed at treating chronic hepatitis B, with patent protection extending to March 2042 [1][2] - The Phase 1 ELIMINATE-B trial is progressing, with dosing for Cohort 3 initiated in Q3 2025, focusing on determining the optimal dose and administration schedule for the treatment [2][4] Company Overview - Precision BioSciences is a clinical stage gene editing company utilizing its proprietary ARCUS platform to develop therapies for diseases with high unmet needs [1][6] - The company aims to deliver lasting cures for a range of genetic and infectious diseases where no adequate treatments exist [6][7] Product and Program Details - PBGENE-HBV is the first and only potentially curative gene editing program specifically designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated HBV DNA [3][4] - The program is currently in a global first-in-human clinical trial, with an estimated 300 million people worldwide suffering from chronic hepatitis B [3] Clinical Trial Information - The ELIMINATE-B trial is enrolling HBeAg-negative chronic hepatitis B patients at sites in Moldova, Hong Kong, New Zealand, and soon in the U.S. [4] - The trial's goal is to define the optimal dose and number of administrations for safely eliminating cccDNA and inactivating integrated HBV DNA [4]
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status